NIH funding opportunities

Faculty of Medicine and Health Sciences: Research Development and Support **19 Oct 2020 (#46)**

[Click on blue hyperlink for further information]

*The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit **www.grants.nih.gov** or **www.sun.ac.za/RDSfunding** (current & archive).*

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notices

- **NOT-AG-21-012 Notice of Special Interest (NOSI): Integrative Studies of Neural Mechanisms Underlying Fundamental Affective Processes in Aging.** The purpose of this NOSI is to inform applicants of NIA's interest in research on the neural mechanisms underlying fundamental affective processes in aging. Grant applications are encouraged to 1) extend research on neural mechanisms underlying affective processes into aging models; and/or 2) seek to "reverse translate" clinical research results on affective processes in aging into model systems that support elucidation of fundamental neural mechanisms. NIA also wishes to encourage collaboration among cognitive and affective neuroscientists and/or investigators working at different levels of neurobiological and behavioral analysis.

Upcoming Deadlines

- Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa):
  Research Training Program due date: 24 November 2020
  Ethical, Legal, and Social Implications Research due date: 1 December 2020
  Open Data Science Platform and Coordinating Center due date: 3 December 2020
  Research Hubs non-AIDS application due date: 8 December 2020
  Research Hubs AIDS application due date: 8 February 2021
- Mobile Health: Technology and Outcomes in LMICs AIDS deadline 3 December 2020
- Emerging Global Leader Award 4 November 2020
- Global Brain Disorders Research 6 November 2020
- Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in LMICs 12 November 2020
- Chronic, Noncommunicable Diseases and Disorders Research Training (NCD-Lifespan) D43 13 November 2020
- Ecology and Evolution of Infectious Diseases Initiative (EEID) 18 November 2020
- Strengthening Institutional Capacity to Conduct Global Cancer Research in Low- and Middle-Income Countries D43 24 June 2021

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- PA-20-185 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- PA-20-184 Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- PA-20-183 Research Project Grant (Parent R01 Clinical Trial Required)
- PA-20-200 NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- PA-20-195 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- PA-20-194 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- PA-20-196 NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Funding Opportunities

1. Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink: PA-20-272** **Type: Admin Supplement**

Application Due Date: Due dates may vary by awarding IC. See the awarding IC's web site or applicable Notice of Special Interest (NOSI) for appropriate Application Due Dates. Applicants may also contact their respective awarding IC. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for administrative supplements are considered prior approval requests (as described in Section 8.1.2.11 of the NIH Grants Policy Statement) and will be routed directly to the Grants Management Officer of the parent award. Although requests for administrative supplements may be submitted through this FOA, there is no guarantee that funds are available from the awarding IC or for any specific grant. All applicants are encouraged to discuss potential requests with the awarding IC. Additionally, prior to submission, applicants must review the awarding IC's web site to ensure they meet the IC's requirements.

Budget: Application budgets are limited to no more than the amount of the current parent award and must reflect the actual needs of the proposed project. The funding mechanism being used to support this program, administrative supplements, can be used to cover cost increases that are associated with achieving certain new research objectives, as long as the research objectives are within the original scope of the peer reviewed and approved project, or the cost increases are for unanticipated expenses within the original scope of the project. Any cost increases need to result from making modifications to the project that would increase or preserve the overall impact of the project consistent with its originally approved objectives and purposes. The project and budget periods must be within the currently approved project period for the existing parent award.

2. Discovery of Cell-based Chemical Probes for Novel Brain Targets (R21 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink: PAR-21-028** **Type: R21**

Application Due Date: Standard dates & Standard AIDS dates apply. Due dates may vary by awarding IC. See the awarding IC's web site or applicable Notice of Special Interest (NOSI) for appropriate Application Due Dates. Applicants may also contact their respective awarding IC. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support investigators who have interest and capability to join efforts for the discovery of cell-based chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds ("validated hits") for chemical optimization and bioassays for testing new analog compounds. Through this FOA, NIH wishes to stimulate research in: 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of NIMH, NIDA, NEI and/or NIA; and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes. The main emphasis of projects submitted under this FOA should be the discovery of cell-based chemical probes. Applicants interested in developing in vivo chemical probes may wish to apply using the companion R01 mechanism, (PAR-21-029).

Budget: Direct costs are limited to $275,000 over a two-year period, with no more than $200,000 in direct costs allowed in any single year.

3. Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink: PAR-21-029** **Type: R01**

Application Due Date: Standard dates & Standard AIDS dates apply. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds ("validated hits") for chemical optimization and bioassays for testing new analog compounds. Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of NIMH, NIDA, NEI, and/or NIA and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes. The main emphasis of projects submitted under this FOA should be the discovery of in vivo chemical probes. Applicants interested in developing cell-based chemical probes may wish to apply using the companion R21 mechanism, (PAR-21-028).

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period may not exceed 4 years.

4. NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink: PAR-21-032** **Type: F32**

Application Due Date:. February 11, 2021, June 9, 2021, October 14, 2021, February 9, 2022, June 8, 2022, October 11, 2022, February 9, 2023, June 8, 2023, and October 10, 2023 and Standard AIDS dates apply. The first AIDS application due date is May 7, 2021.Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this award is to support outstanding scientific training of highly promising postdoctoral candidates with outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start of the proposed postdoctoral position to within 12 months after starting in the proposed postdoctoral position. This NINDS F32 seeks to foster early, goal-directed planning and to encourage applications for bold and/or innovative projects by the candidate that have the potential for significant impact. Inclusion of preliminary data is strongly discouraged; rather, this F32 seeks innovative research ideas and thoughtful plans for training and mentorship that will facilitate the development of the postdoctoral fellow into an outstanding scientist. Applications are expected to incorporate strong training in quantitative reasoning and the quantitative principles of experimental design and analysis. Support by this program is limited to the first 4 years of a candidate's activity in a specific laboratory or research environment, so as to further encourage early,

thoughtful planning and timely completion of "mentored training" within a particular lab or environment. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.

Budget: Individuals may receive up to 3 years of aggregate Kirschstein-NRSA support at the postdoctoral level, including any combination of support from institutional training grants. For this FOA, support will be provided only during the first 4 years of postdoctoral experience in any one particular laboratory or research environment. For example, if an award is made 18 months after the start of the postdoctoral position in the fellowship laboratory or research environment, the award duration will be for a maximum of 30 months. Fellowship awards will contribute to the combined cost of tuition and fees at the rate in place at the time of award. See https://researchtraining.nih.gov/resources/policy-noticesFellowship awards do not include a separate reimbursement for indirect costs (also known as Facilities & Administrative [F&A] Costs). Instead of costs for administering fellowships are covered by the Institutional Allowance. See https://researchtraining.nih.gov/resources/policy-notices

5. New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not Allowed)

Letter of Intent: While letters of intent are normally requested 30 days before the application due date, for this FOA they are requested by December 15, 2020. **Hyperlink: RFA-CA-20-049** **Type: UG3/UH3**

Application Due Date: Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) and National Institute of Environmental Health Sciences (NIEHS) invite applications to support innovative scientific research in new prospective cohorts that addresses knowledge gaps in cancer etiology and carcinogenesis processes with a focus on environmental exposures.

Applicants are encouraged to use validated and reproducible innovative techniques to measure environmental exposures relevant to the proposed scientific research questions. The cohorts should include racial/ethnic minorities and understudied populations to address the unequal burden of cancer that currently exists in those populations. In this FOA, environmental exposures refer to physical, chemical, and biological factors external to a person, and related behavioral factors. This FOA is published in parallel with RFA-CA-20-050 "New Cohorts for Environmental Exposures and Cancer Risk (CEECR) Coordinating Center (U24 Clinical Trial Not Allowed)". New prospective cohorts and the Coordinating Center funded under these FOAs together will constitute the Cohorts for Environmental Exposure and Cancer Risk (CEECR) program.

Budget: NCI and NIEHS intend to commit $6.5 million in FY 2021 to fund approximately five awards. Application budgets are limited to $750,000 direct costs per year in years 1 and 2. Budgets in years 3-6 are not limited but must reflect the actual needs of the proposed project. The proposed project period for the initial development phase (UG3) must not exceed 2 years and the total duration of the UG3/UH3 phases combined may not exceed 6 years.

6. Collaborative Approaches to Engineer Biology for Cancer Applications (U01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink**: **RFA-CA-20-054** **Type: U01**

Application Due Date: January 15, 2021Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This funding opportunity announcement (FOA) invites applications to develop and apply innovative synthetic biology approaches to address challenges across the spectrum of cancer research. Projects will be required to apply a technology, based on an engineered biological system, to an important and well-defined cancer research question. Collaborative transdisciplinary teams are expected with PIs representing expertise in cancer research, engineering, and other disciplines relevant to synthetic biology.

Budget: NCI and NIBIB intend to commit an estimated total of $4.2M in FY 2021 to fund 4-6 awards. Application budgets are limited to $499,999 in direct costs per year and must reflect the actual needs of the proposed project. The maximum project period is 5 years.

7. Utilizing In Vitro Functional Genomics Advances for Gene-Environment (G x E) Discovery and Validation (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink: RFA-ES-20-018** **Type: R01**

Application Due Date: February 1, 2021 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this funding opportunity is to solicit applications that fully integrate recent innovative advances of in vitro functional genomics tools/technologies and approaches for environmental health and toxicology research. The overall goal of this NIEHS led initiative is to generate proof-of-principle studies incorporating these new in vitro approaches, together with well characterized exposures, to further our understanding of gene-environment (G x E) interactions in complex human disorders.

Budget: NIEHS intends to commit $4 million in FY 2022 to fund approximately 6 awards. NHGRI intends to commit $.5 million in FY 2022 to potentially co-fund approximately 2 awards. NCI intends to commit $1 million in FY 2022 to fund one award and potentially co-fund one additional award. Application budgets are limited to $499,999.00 Direct Costs per year. The maximum project period is 5 years.